Curasight A/S approved for listing at Spotlight Stock Market
Curasight is built on more than a decade of research at the University of Copenhagen and Rigshospitalet, the National University Hospital of Denmark. Over the last several years Professor Andreas Kjaer has together with a scientific team developed the concept of PET imaging of the receptor (uPAR), a known biomarker of cancer aggressiveness, to be used for improved diagnosis, risk stratification and treatment planning/ monitoring in multiple types of cancer.Curasight A/S, is a danish biotech company registered in 2013 with focus on addressing the need for improved diagnosis and treatment of